TML-OTE-IHT-22

TML-OTE-IHT-22 is a preclinical-stage oral analgesic candidate being developed by Themis Medicare. Formulated as a tablet, it is intended for the management of pain. The candidate belongs to the 'TML-OTE' series within Themis Medicare's pipeline, which typically designates Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) that incorporate Novel Drug Delivery Systems (NDDS). The 'IHT' suffix likely refers to a proprietary formulation technology designed to enhance the drug's pharmacokinetic properties, such as solubility or release rate, to improve therapeutic outcomes. As a preclinical asset, TML-OTE-IHT-22 is currently undergoing laboratory and animal studies to establish its safety and efficacy profile before potentially progressing to human clinical trials.